ANGLE PLC has opened up "a major market opportunity" with breast cancer partnership | News Direct

ANGLE PLC has opened up "a major market opportunity" with breast cancer partnership

ANGLE PLC
News release by ANGLE PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | April 20, 2023 04:20 AM Eastern Daylight Time

 

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Thomas Warner from Proactive after announcing a development partnership with BioView.

 

The partnership will see the two firms develop to create a circulating tumour cell (CTC) HER2 assay for breast cancer that could ultimately enable hospitals worldwide to access technology that measures HER2 status in breast cancer patients.

 

Newlands says it has opened up "a major market opportunity" with the partnership.

 

 

Contact Details

 

Proactive UK Ltd

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

HealthbiopsyOncologyCancerbreast cancer